Although the comparison did not reach statistical significance due to limited sample size, patients who had ADAM15+, EGFR+, or HER2+ CTCs trended toward reduced overall survival.
← all excerpts
Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics.
1
—
—